Shine Medical closed an $11.4 million funding round for its method of generating a low-energy neutron source for medical imaging that uses a particle accelerator instead of a nuclear reactor.
NxStage Medical Inc.
Dialysis: NxStage keeps fighting Medicare rules for home hemodialysis
NxStage Medical (NSDQ:NXTM) is still fighting the Centers for Medicare & Medicaid Services on its proposed rule for home hemodialysis treatment.
The dialysis devices maker submitted a public comment on the updated rule, calling for more support for HHD therapy, especially in terms of training.
Dialysis: NxStage Medical reports record sales, hits new Wall Street low
NxStage Medical (NSDQ:NXTM) notched a new low watermark for the year, despite reporting a strong 2nd quarter with records sales.
NXTM shares briefly hit $13.20 today, the lowest they’ve been in the last 52 weeks. Shares regained few cents by the early afternoon to trade at $13.34, still down 16% on the day.
NxStage Medical to Medicare: Really?
NxStage Medical (NSDQ:NXTM) regained some points on Wall Street after issuing public statement challenging the Centers for Medicare & Medicaid on its uninspiring policies for home hemodialysis.
No near-term upside for NxStage as Medicare maintains home hemodialysis status quo
The Centers for Medicare & Medicaid Services last night released an updated rule for reimbursement of home hemodialysis treatment that wasn’t much of an update at all.
CMS maintained the reimbursement status quo, dashing some investors’ hopes of a near-term upside for NxStage Medical (NSDQ:NXTM).
NxStage Medical lands Aetna reimbursement win
Health insurance and technology giant Aetna modified its policy on NxStage Medical’s (NSDQ:NXTM) System One home hemodialysis system. dubbing the device "medically necessary" rather than "experimental."
Biomet considers spinning out dental | Wall Street Beat
In a growing trend among device makers, Biomet Inc. announced that it’s exploring strategic options to spin out its 3i dental devices division.
The company is just testing the waters and a split isn’t guaranteed, but if completed the move will follow in some notable footsteps.
Details emerge on ex-Stryker CEO MacMillan’s departure | Wall Street Beat
MAKO’s plunge may be good news for buyers | Wall Street Beat
Mako Surgical (NSDQ:MAKO) has had a tough month on Wall Street, with shares having lost 45% since the end of April, but not everyone is running for the hills.
Earlier this week a company director, Frederick Moll, picked up another 5,000 shares at $24.15 each, representing the 1st insider buy on the open market since late last year.
Another solid quarter for NxStage Medical
Investors declined to reward NxStage Medical (NSDQ:NXTM) today for another in a string of solid quarters, sending share prices down YY% despite higher sales, narrowed losses and re-affirmed guidance.